CN104784411A - Pig respiratory tract diseases prevention and treatment drug composition, premix and matching material thereof - Google Patents
Pig respiratory tract diseases prevention and treatment drug composition, premix and matching material thereof Download PDFInfo
- Publication number
- CN104784411A CN104784411A CN201410020332.6A CN201410020332A CN104784411A CN 104784411 A CN104784411 A CN 104784411A CN 201410020332 A CN201410020332 A CN 201410020332A CN 104784411 A CN104784411 A CN 104784411A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- group
- pharmaceutical composition
- pig
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 164
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 239000000463 material Substances 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title abstract description 29
- 208000018569 Respiratory Tract disease Diseases 0.000 title abstract description 13
- 230000002265 prevention Effects 0.000 title abstract description 11
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims abstract description 28
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical group CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 claims abstract description 18
- 229960003760 florfenicol Drugs 0.000 claims abstract description 18
- 229950007634 kitasamycin Drugs 0.000 claims abstract description 14
- XYJOGTQLTFNMQG-KJHBSLKPSA-N leucomycin V Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1 XYJOGTQLTFNMQG-KJHBSLKPSA-N 0.000 claims abstract description 14
- 229930194936 Tylosin Natural products 0.000 claims abstract description 13
- 239000004182 Tylosin Substances 0.000 claims abstract description 13
- 229960004059 tylosin Drugs 0.000 claims abstract description 13
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 claims abstract description 13
- 235000019375 tylosin Nutrition 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 229960000223 tilmicosin Drugs 0.000 claims abstract description 11
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- LLYYNOVSVPBRGV-MVNKZKPCSA-N valnemulin Chemical compound CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 LLYYNOVSVPBRGV-MVNKZKPCSA-N 0.000 claims abstract description 9
- 229950008166 valnemulin Drugs 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims description 52
- 239000004615 ingredient Substances 0.000 claims description 48
- 208000023504 respiratory system disease Diseases 0.000 claims description 37
- 239000000843 powder Substances 0.000 claims description 31
- 239000012467 final product Substances 0.000 claims description 15
- OLLSDNUHBJHKJS-XKORHJEPSA-N [(2s,3s,4r,6s)-6-[(2r,3s,4r,5r,6r)-6-[[(4r,5s,6s,7r,9r,11e,13e,15r,16r)-4-acetyloxy-16-ethyl-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13-trimethyl-2,10-dioxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(d Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](OC(C)=O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 OLLSDNUHBJHKJS-XKORHJEPSA-N 0.000 claims description 12
- -1 taimulin Chemical compound 0.000 claims description 8
- 239000011236 particulate material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 abstract description 6
- 229960004885 tiamulin Drugs 0.000 abstract description 6
- 239000000273 veterinary drug Substances 0.000 abstract description 2
- 244000281702 Dioscorea villosa Species 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 80
- 241000282898 Sus scrofa Species 0.000 description 76
- 210000004072 lung Anatomy 0.000 description 14
- 208000012353 Contagious Pleuropneumonia Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000008977 mycoplasmal pneumonia of swine Diseases 0.000 description 11
- 230000000069 prophylactic effect Effects 0.000 description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 10
- 206010025482 malaise Diseases 0.000 description 10
- 230000029058 respiratory gaseous exchange Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 7
- 206010039088 Rhinitis atrophic Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 231100000915 pathological change Toxicity 0.000 description 7
- 230000036285 pathological change Effects 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 6
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- NESIVXZOSKKUDP-ARVJLQODSA-N (4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4s,5s,6r)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-7-[2-[(3s,5r)-3,5-dimethylpiperidin-1-yl]ethyl]-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13 Chemical compound OP(O)(O)=O.O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O NESIVXZOSKKUDP-ARVJLQODSA-N 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 239000001530 fumaric acid Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229960000757 tilmicosin phosphate Drugs 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- MFBPRQKHDIVLOJ-AFFLPQGKSA-N 133868-46-9 Chemical compound Cl.CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 MFBPRQKHDIVLOJ-AFFLPQGKSA-N 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 3
- 241000711493 Porcine respiratory coronavirus Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002554 disease preventive effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000606807 Glaesserella parasuis Species 0.000 description 2
- 206010069767 H1N1 influenza Diseases 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 2
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 2
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000725681 Swine influenza virus Species 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000021053 average weight gain Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000009589 serological test Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000195622 Astasia Species 0.000 description 1
- 241001037822 Bacillus bacterium Species 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010052535 Small intestinal haemorrhage Diseases 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a pig respiratory tract diseases prevention and treatment drug composition, a premix and a matching material thereof, and belongs to the field of veterinary drugs and premixes. The drug composition of the present invention comprises, by weight, 40-95 parts of a traditional Chinese medicine component, and 10-60 parts of a chemical drug component, wherein the traditional Chinese medicine component is prepared from the fructus arctii, roripa montana and common yam rhizome, and the chemical drug component is selected from florfenicol, tilmicosin, tiamulin, valnemulin, acetylisovaleryltylosin, tylosin, kitasamycin and a salt thereof. The drug compositions of the present invention is suitable for pig respiratory tract diseases prevention and treatment, has characteristics of significant treatment effect, high safety, stable formulation, controllable quality, simple preparation process and the like, is suitable for industrial production, and can further be added to the feed so as to be used for preparation of pig growth promoting feed such as premixes, matching materials and the like.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for preventing and treating porcine respiratory disease, premix material and batch, belonging to veterinary drug and premix material field.
Background technology
Porcine respiratory disease is that pig farm is the most common, endanger the most serious disease one of.Sickness rate is usually at 30-70%, and mortality rate 15-20%, causes serious economic loss to pig farm.Clinical symptoms shows as successional cough, accelerated breathing, ventral breathing, dehisces to breathe, and in sitting position of dog gesture, has sound of significantly stridulating, loss of appetite or exhausted, gradual becoming thin of giving up, mostly dead because of exhaustion or infection other diseases; Sow abortion, stillborn fetus, mummy tire, to return feelings rate high; Piglet and fattening pig is weak, diarrhoea, poor growth or stagnation.As can be seen here, respiratory tract disease increases mortality rate, reduces fertility performance, reduces carcase quality, increases medical expense, increases management cost, so become the No.1 disease affecting global pig industry economic benefit.
A kind of mixed infection that porcine respiratory disease is usually caused by factors such as one or more antibacterials, virus, environmental stresses, and be difficult to eradicate.Cause the original mycoplasma hyopneumoniae of the primary disease of porcine respiratory disease (MH), virus levied in porcine reproductive respiratory trace integration (PRRSV is commonly called as reproductive and respiratory syndrome), PRV (Pseudorabies virus) (PRV), swine influenza virus (SIV), PRCV (Porcine Respiratory Coronavirus) (PRCV), Actinobacillus pleuropneumoniae (APP), pig circular ring virus two type (PCV2); The original pasteurella multocida of secondary disease (PM), Streptococcus suis (SS), haemophilus parasuis (HP), bordetella branchiseptica (BB); The main arch-criminal causing respiratory tract disease is mycoplasma hyopneumoniae.It destroys the defensive barrier of respiratory tract, makes other pathogen be easy to enter respiratory tract and pulmonary, causes Secondary cases mixed infection.Especially MH and PRRSV can change the respond of respiratory immunity system, reduces pig mucosal immunity resistance, increases pig to the susceptibility of respiratory tract disease; Animal house door and window is closed too tight, improper ventilation, and cause ammonia in house to increase, stocking density is large, and humidity is high, and sanitary condition is poor, and the environmental factors such as the stimulation of feed meal foot couple respiratory tract is also the inducement of respiratory tract disease generation.Wherein porcine contagious pleuropneumonia, atrophic rhinitis, mycoplasmal pneumonia of swine are three large respiratory tract diseases that are universally acknowledged, harm Pig Industry industry, when influenza virus, Pseudorabies virus and porcine reproductive respiratory syndrome (PRRS) virus exist, sickness rate will significantly increase, the state of an illness will be more serious, and loss also will be more heavy.Owing to causing the pathogen of respiratory tract disease complicated, and the generation of drug resistance, cause current vaccine or chemicals cannot prevention and control porcine respiratory disease completely, be therefore necessary to research and develop newtype drug, clinically make us thorny porcine respiratory disease problem to solve.
Chinese herbal medicine is pure natural substance, containing multiple biological effective components, there is antibacterial, antiinflammatory, not easily produce the features such as drug resistance, low toxicity, noresidue or low-residual, regulate body allomeric function, improve the resistance against diseases of body self, prolonged application is safe and reliable has medicine and nutrient double effects concurrently.Particularly Chinese medicine has obvious advantage when treating respiratory tract disease, treats by dialectical the effect reaching and get instant result.Chemistry antibacterials have that effect is fast, strong drug action, the advantage such as easy to use.Both combine, then can learn from other's strong points to offset one's weaknesses, inside and outside take into account, entire and part is laid equal stress on, and plays the effect brought out the best in each other.
In the process of Chinese medicine and western medicine conbined usage, because prescription is not rigorous, medication is numerous and jumbled, compatibility not science, improper use, curative effect is stable not, does not even not only reach expected effect, and respiratory tract disease can be caused on the contrary more serious.Therefore need to hold reasonable formula and principle of medication, just can obtain the effect of getting twice the result with half the effort.
Summary of the invention
The object of the present invention is to provide a kind of efficient, safe, quick-acting pharmaceutical composition for preventing and treating porcine respiratory disease, thus solve the problem, and overcome the deficiency of existing means of prevention.
Another object of the present invention is to provide this for preventing and treating preparation method and the application thereof of the pharmaceutical composition of porcine respiratory disease.
Present invention also offers comprise this pharmaceutical composition premix material, batch or particulate material.
The object of the invention is to be achieved through the following technical solutions:
The invention provides a kind of pharmaceutical composition for preventing and treating porcine respiratory disease, comprising following weight parts component: Chinese medicine ingredients 40-95 part, chemical medicine composition 1-60 part; Described Chinese medicine ingredients is made up of the component of following weight parts: Fructus Arctii 1-30 part, Semen Lepidii (Semen Descurainiae) 1-30 part, Rhizoma Dioscoreae 10-80 part; Described chemical medicine composition is selected from florfenicol, tilmicosin, taimulin, valnemulin, Aivlosin, tylosin, kitasamycin and salt thereof.
In a preferred embodiment, the pharmaceutical composition of control porcine respiratory disease of the present invention comprises following weight parts component: Chinese medicine ingredients 50-90 part, chemical medicine composition 5-50 part; Described Chinese medicine ingredients is made up of the component of following weight parts: Fructus Arctii 3-20 part, Semen Lepidii (Semen Descurainiae) 3-20 part, Rhizoma Dioscoreae 30-70 part; Described chemical medicine composition is selected from florfenicol, tilmicosin, taimulin, valnemulin, Aivlosin, tylosin, kitasamycin and salt thereof.
In a further preferred embodiment, the pharmaceutical composition of control porcine respiratory disease of the present invention comprises the parts by weight of component of following weight parts: Chinese medicine ingredients 60-85 part, chemical medicine composition 10-40 part; Described Chinese medicine ingredients is made up of following ingredients weight parts: Fructus Arctii 6-15 part, Semen Lepidii (Semen Descurainiae) 6-15 part, Rhizoma Dioscoreae 40-60 part; Described chemical medicine composition is selected from florfenicol, tilmicosin, taimulin, valnemulin, Aivlosin, tylosin, kitasamycin and salt thereof.
In further preferred embodiment, the pharmaceutical composition of control porcine respiratory disease of the present invention comprises following weight parts component: Chinese medicine ingredients 80 parts, chemical medicine composition 20 parts; Described Chinese medicine ingredients is made up of the component of following weight parts: Fructus Arctii 10 parts, Semen Lepidii (Semen Descurainiae) 10 parts, Rhizoma Dioscoreae 50 parts; Described chemical medicine composition is selected from florfenicol, tilmicosin, taimulin, valnemulin, Aivlosin, tylosin, kitasamycin and salt thereof.
Present invention also offers the preparation method of this pharmaceutical composition, it comprises the steps:
(1) take each taste Chinese medicine by weight ratio respectively, Fructus Arctii, Semen Lepidii (Semen Descurainiae), Rhizoma Dioscoreae powder are broken into fine powder, obtain Chinese medicine ingredients;
(2) by weight taking Chinese medicine ingredients and chemical medicine composition respectively again, by the two mix homogeneously, to obtain final product.
Pharmaceutical composition of the present invention can be used for the medicine preparing control porcine respiratory disease.
Drug component in pharmaceutical composition of the present invention and consumption thereof get by repeatedly practising in a large number.Pharmaceutical composition of the present invention can be used for preventing and treating porcine respiratory disease.
Pharmaceutical composition of the present invention also can add in feedstuff, for the preparation of the somatotrophic feedstuff of pig, as: premix material provided by the invention, also can be used for preparing the feedstuff such as batch, particulate material.
The present invention adopts combining method of chinese-western medicine to prevent and treat porcine respiratory disease.Chinese medicine antibacterial, antiinflammatory, antipyreticly to relieve inflammation or internal heat, immunity moderation, in side, the lung moistening of Fructus Arctii energy again can sharp lung, can also expectorant fall the inverse of lung qi, makes inverse cyclostrophic and descending, can priming power fast in assigning focus; Semen Lepidii (Semen Descurainiae) eliminating pathogen from the lung for relieving asthma, stops up stagnant expectorant in eliminating the pathogens from the lung, strengthen the power of Fructus Arctii effect; Rhizoma Dioscoreae the kidney invigorating is held concurrently spleen reinforcing lung, grows Kidney-Yin greatly, and is full of the power of convergence, controls the merit of breathing heavily the strongest.Three medicines use, reinforcing and reducing are helped mutually, bring out the best in each other, relieving cough, relieving asthma Be very effective, to become to pacify the merit of lung.Western medicine is antibacterial, fast onset effect, and skeptophylaxis regulates, relieving cough and asthma, prevents secondary infection, reduces dead.Pharmaceutical composition reasonable recipe of the present invention take animal as entirety, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, treating both the principal and secondary aspects of a disease, thus reaches the object effectively controlling porcine respiratory disease fast, and focuses on dealing with problems arising from an accident, and watch for animals body, is the scheme that it is at all remote.
Advantage and beneficial effect for preventing and treating porcine respiratory disease pharmaceutical composition of the present invention is:
(1) the present invention is Chinese medicine and western medicine compound preparation, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, treating both the principal and secondary aspects of a disease;
(2) pharmaceutical composition reasonable recipe of the present invention, science;
(3) pharmaceutical composition good effect of the present invention, instant effect, easy to use, safe, rehabilitation is fast;
(4) drug combination preparation of the present invention is stable, preparation technology is simple, with low cost, constant product quality, controlled, has the stronger market competitiveness.
Detailed description of the invention
Following examples for illustration of the present invention, but are not used for limiting the scope of the invention.
Embodiment 1
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 1 part, Semen Lepidii (Semen Descurainiae) 1 part, Rhizoma Dioscoreae 10 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 40 parts, florfenicol 1 part, mix homogeneously, to obtain final product.
Embodiment 2
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 30 parts, Semen Lepidii (Semen Descurainiae) 30 parts, Rhizoma Dioscoreae 80 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 95 parts, florfenicol 60 parts, mix homogeneously, to obtain final product.
Embodiment 3
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 3 parts, Semen Lepidii (Semen Descurainiae) 3 parts, Rhizoma Dioscoreae 30 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 50 parts, florfenicol 5 parts, mix homogeneously, to obtain final product.
Embodiment 4
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 20 parts, Semen Lepidii (Semen Descurainiae) 20 parts, Rhizoma Dioscoreae 70 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 90 parts, florfenicol 50 parts, mix homogeneously, to obtain final product.
Embodiment 5
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 6 parts, Semen Lepidii (Semen Descurainiae) 6 parts, Rhizoma Dioscoreae 40 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 60 parts, florfenicol 10 parts, mix homogeneously, to obtain final product.
Embodiment 6
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 15 parts, Semen Lepidii (Semen Descurainiae) 15 parts, Rhizoma Dioscoreae 60 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 85 parts, florfenicol 40 parts, mix homogeneously, to obtain final product.
Embodiment 7
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 10 parts, Semen Lepidii (Semen Descurainiae) 10 parts, Rhizoma Dioscoreae 50 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 80 parts, florfenicol 20 parts, mix homogeneously, to obtain final product.
Embodiment 8
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 2 parts, Semen Lepidii (Semen Descurainiae) 2 parts, Rhizoma Dioscoreae 15 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 45 parts, Acetylisovaleryl Tylosin Tartrate 2 parts, mix homogeneously, to obtain final product.
Embodiment 9
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 25 parts, Semen Lepidii (Semen Descurainiae) 25 parts, Rhizoma Dioscoreae 75 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 92 parts, fumaric acid tiamulin 55 parts, mix homogeneously, to obtain final product.
Embodiment 10
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 5 parts, Semen Lepidii (Semen Descurainiae) 5 parts, Rhizoma Dioscoreae 35 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 55 parts, tylosin phosphonate 8 parts, mix homogeneously, to obtain final product.
Embodiment 11
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 18 parts, Semen Lepidii (Semen Descurainiae) 18 parts, Rhizoma Dioscoreae 65 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 88 parts, kitasamycin 45 parts, mix homogeneously, to obtain final product.
Embodiment 12
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 8 parts, Semen Lepidii (Semen Descurainiae) 8 parts, Rhizoma Dioscoreae 45 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 70 parts, tilmicosin phosphate 15 parts, mix homogeneously, to obtain final product.
Embodiment 13
(1) Chinese crude drug containing following weight is taken: Fructus Arctii 12 parts, Semen Lepidii (Semen Descurainiae) 12 parts, Rhizoma Dioscoreae 55 parts, be broken into fine powder by traditional Chinese medicine powder, for subsequent use as Chinese medicine ingredients.
(2) following weight composition is taken respectively again: Chinese medicine ingredients 82 parts, valnemulin hydrochloride 30 parts, mix homogeneously, to obtain final product.
For showing pharmaceutical composition of the present invention control porcine viral diseases effect, applicant has carried out clinical observation on the therapeutic effect test to this pharmaceutical composition further, sets forth the beneficial effect of medicine of the present invention below by way of test example further.
The observation of test example 1 pair of artificial challenge's porcine contagious pleuropneumonia therapeutic effect
Select healthy ablactational baby pig 105,28 ages in days, body weight 7-8 kilogram, not inoculated porcine contagious pleuropneumonia defence line coli vaccine, serological test confirms porcine contagious pleuropneumonia defence line bacillus negative antibody, breeding observing 7 days under test conditions.Test pig is divided into 7 groups at random, often organizes 15, test 1-4 group is pharmaceutical composition group of the present invention, and use the embodiment of the present invention 1, embodiment 3, embodiment 5, embodiment 7 pharmaceutical composition to treat after infection respectively, feedstuff per ton adds 500 grams; Testing 5 groups is control drug group, and use 10% florfenicol powder to treat after infecting, feedstuff per ton adds 800 grams; Testing 6 groups is positive controls, only infects not administration; Testing 7 groups is negative control group, does not infect not administration.The pig testing 1 group to 6 groups carries out artificial challenge's porcine contagious pleuropneumonia defence line bacillus, and it is 1 × 10 that every pig collunarium inoculates every milliliter of bacteria containing amount
9porcine contagious pleuropneumonia defence line bacillus bacterium liquid 5 milliliters, tests 7 groups every pig collunarium inoculation normal saline 5 milliliters.Artificial challenge, after 4 hours, occurs after the symptoms such as spirit is slightly depressed until part pig, and namely test 1-5 group uses pharmaceutical composition of the present invention and control drug to treat respectively, successive administration 5 days, then continues observation 10 days.The clinical manifestation of duration of test close observation pig, as changes such as breathing, appetite, the mental status, and records morbidity number and the death toll of each group, and the body weight before test and after off-test.Inspection is cutd open to all dead pigs and off-test rear section pig, observes each organ disease, and carry out antibacterial culturing, to determine whether as contagious pleuropneumonia defence line bacillus infection.
The pig testing 6 groups of positive controls is after artificial challenge, and start to occur that spirit is extremely depressed, appetite declines, rapid breathing, fever, and astasia, does not eat sleepingly, when the course of disease occurs serious, occurs dehiscing to loll, and mouth and nose are bled color foam liquid, and finally fall down to the ground death.36-48 hour after infecting, positive controls pig is all dead.Dead pig cuts open inspection pathological changes, pneumorrhagia, necrosis, and liver is slightly swollen, and there is the downright bad point of canescence on surface.Spleen is enlargement slightly, and intestinal mucosa, duodenal hemorrhage are serious, and pericardium has a large amount of opaque weak yellow liquid, or cellulose sample exudate.Lung, liver detect a large amount of contagious pleuropneumonia defence lines bacillus.Test 7 groups of negative control group pigs, cut open inspection and have no obvious pathological change.Illustrate that this experimental labor infects successfully, test is set up.Test 1-5 group medicine composite for curing group of the present invention and control drug treatment group, its pathological change is similar to positive controls, and in chronic pneumonia district of hardening as seen through dead pig, pneumonia focus is gangrenosum acne or suppurative focus.Liver slightly enlargement, has downright bad point.Intestinal mucosa lymphadenectasis, hemorrhage.Lung, liver detect contagious pleuropneumonia defence line bacillus.Test 1-4 group medicine composite for curing of the present invention group is cutd open inspection through the pig that treatment recovery from illness is not dead and is had no obvious pathological changes, does not detect contagious pleuropneumonia defence line bacillus.Test 5 groups of control drug groups through the pig that treatment recovery from illness is not dead cut open inspection still visible lungs slightly wait suppurative focus in various degree.Result of the test is in table 1.
Table 1 artificial challenge porcine contagious pleuropneumonia therapeutic test result
Result of the test shows, and uses merely compared with florfenicol, and embodiment 1, embodiment 3, embodiment 5, embodiment 7 pharmaceutical composition have good therapeutic effect to porcine contagious pleuropneumonia, can promote pathological tissues rehabilitation, and growth-promoting effect are obvious.Wherein effect is it is preferred that embodiment 7, is secondly embodiment 5 and embodiment 3, is finally embodiment 1.
The observation of test example 2 pairs of porcine respiratory disease preventive effects
Select have the pig farm of respiratory tract morbidity history to carry out prophylactic tria observation.Scale pig farm, Beijing is perplexed by respiratory tract disease all the year round, and winter-spring season is particularly serious, shows as cough with asthma, dyspnea, severe patient ventral breathing, and by hair slightly disorderly, weightening finish reduces, and death increases.Therefore select this pig farm to carry out preventive effect evaluation.
1000, this pig farm ablactational baby pig is divided into 5 groups at random, is respectively the Ith group, the IIth group, the IIIth group, the IVth group and the Vth group, often organize 200 piglets.Ith group is medicine group to the IVth group, gives the embodiment of the present invention 2,4,6,7 pharmaceutical composition respectively, adds embodiment of the present invention pharmaceutical composition 200 grams, continuous use 14 days according to feedstuff per ton.Vth group is blank group, does not give any medicine.After administration terminates, observe 14 days, result of the test is in table 2.
Table 2 porcine respiratory disease prophylactic tria result
| Group | Test pig number (head) | Morbidity pig number (head) | Dead pig number (head) | Sickness rate (%) |
| Ith group | 200 | 2 | 0 | 1 |
| IIth group | 200 | 3 | 0 | 1.5 |
| IIIth group | 200 | 2 | 0 | 1 |
| IVth group | 200 | 0 | 0 | 0 |
| Vth group | 200 | 61 | 5 | 30.5 |
Result of the test shows, pharmaceutical composition of the present invention effectively can prevent porcine respiratory disease.Prevention porcine respiratory disease effect is it is preferred that embodiment 7 pharmaceutical composition, and sickness rate is 0, and mortality rate is 0, and effective percentage can reach 100%, is secondly embodiment 6, embodiment 4, embodiment 2 pharmaceutical composition, all significant difference compared with blank group.
The observation of test example 3 pairs of artificial challenge's mycoplasmal pneumonia of swine therapeutic effect
Select body weight 10-12 kilogram of sodium selenite 100, not inoculated porcine mycoplasmal vaccine, serological test confirms porcine mycoplasmal negative antibody, breeding observing 7 days under test conditions.Test pig is divided into 5 groups at random, often organizes 20, test I group, use the embodiment of the present invention 8 to treat after infecting, feedstuff per ton adds 1 kilogram; Test II group, use the pure Chinese medicine composition of the embodiment of the present invention 8 of not buccal medicine Acetylisovaleryl Tylosin Tartrate to treat after infection, feedstuff per ton adds 1 kilogram; Use 5% Acetylisovaleryl Tylosin Tartrate pre-mixing agent to treat after testing III group of infection, feedstuff per ton adds 1 kilogram; Testing IV group is positive controls, only infects not administration; Testing V group is negative control group, does not infect not administration.The pig of test I to IV group uses mycoplasma virulent strain to carry out artificial challenge, tests V group every pig intraperitoneal injection of saline.Artificial challenge is after 20 days, and after disease symptom appears in part pig, namely test I-III group uses medicine to treat respectively, successive administration 5 days, continue observation again 20 days, slaughter and carry out pathological changes observation and record each lobe of the lung pathological changes index and add up pulmonary lesion index, pulmonary lesion standards of grading are in table 3.
Table 3 each lobe of the lung lesion score standard
| The lobe of the lung area (%) of specific Damage | Score |
| 0 | 0 |
| 1-25 | 1 |
| 26-50 | 2 |
| 51-75 | 3 |
| >75 | 4 |
The clinical manifestation of duration of test close observation pig, as changes such as breathing, appetite, the mental status, and the body weight before record test and after off-test.Result of the test is in table 4.
Table 4 artificial challenge mycoplasmal pneumonia of swine therapeutic test result
| Group | Test pig number (head) | Mean pulmonary pathological changes index | Average initial weight (kg) | Average end heavy (kg) | Average weight gain (kg) | Body weight increase rate (%) |
| Test I group | 20 | 1.6 | 12.78±1.03 | 45.14±1.01 | 32.36 | 105.17 |
| Test II group | 20 | 7.3 | 13.01±1.16 | 42.13±1.11 | 29.12 | 94.64 |
| Test III group | 20 | 9.6 | 13.06±1.21 | 41.62±1.07 | 28.56 | 92.82 |
| Test IV group | 20 | 21.8 | 12.89±1.08 | 35.80±1.06 | 22.91 | 74.46 |
| Test V group | 20 | 2.4 | 12.56±1.23 | 43.33±1.31 | 30.77 | 100 |
Result of the test shows; the embodiment of the present invention 8 pharmaceutical composition is obviously better than pure Chinese medicine composition or alone chemical medicine Acetylisovaleryl Tylosin Tartrate in treatment artificial challenge mycoplasmal pneumonia of swine; effectively can treat mycoplasmal pneumonia of swine; in pulmonary lesion curative effect compared with positive controls significant difference, and growth-promoting effect is obvious.
The observation of test example 4 pairs of mycoplasmal pneumonia of swine therapeutic effect
Mycoplasmal pneumonia of swine, also known as swine enzootic pneumonia, is cause one of disease that pig industry economic loss is the most serious.Sickness rate high mortality is low, although appetite is normal, and growth retardation, hypoevolutism.When secondary infection, cough can be caused to increase the weight of, body temperature raises, and severe patient exhaustion is dead.Mycoplasma is by air borne, and swinery infection rate is high, and mycoplasma pneumonia is one of swine diseases of the most difficult generally acknowledged purification.It is popular in rising trend year by year, brings about great losses to pig industry.
Pig farm, Hubei Province, there is the symptoms such as cough, asthma, ventral breathing in 40-60 age in days piglet, pathology cuts open the inspection display lobe of the lung carnification, bronchial lymph nodes and mediastinal lymph node enlargement.Be mycoplasmal pneumonia of swine through comprehensive diagnos.
Morbidity pig is divided into 4 groups at random, often organizes 45.1st group gives the embodiment of the present invention 9 pharmaceutical composition and treats, the 2nd group of pure Chinese medicine composition giving the embodiment of the present invention 9 of not buccal medicine fumaric acid tiamulin is treated, 3rd group gives 10% fumaric acid tiamulin pre-mixing agent and treats, 4th group is blank group, does not give any Drug therapy.1st group and the 2nd group adopts drinking water administration method to give pharmaceutical composition, gets 80 DEG C of hot water 10 kilograms and add pharmaceutical composition 15 grams, soak three times, each 30 minutes, merge three medicinal liquids, be diluted with water to 50 kilograms, and medicinal liquid is drunk for pig, and medicinal residues spice is fed; 60 gram of 10% fumaric acid tiamulin pre-mixing agent is dissolved in 50 kg of water, drinks for pig by the 3rd group, and treat 7 days all continuously, then continue observation 14 days, result of the test is in table 5.
Table 5 piglet mycoplasma pneumonia therapeutic test result
| Group | Test pig number (head) | Cure pig number (head) | Cure rate (%) | Death toll (head) | Mortality rate (%) |
| 1st group | 45 | 45 | 100 | 0 | 0 |
| 2nd group | 45 | 21 | 46.7 | 1 | 2.2 |
| 3rd group | 45 | 36 | 80 | 1 | 2.2 |
| 4th group | 45 | 6 | 13.3 | 3 | 6.7 |
Result of the test shows, the embodiment of the present invention 9 pharmaceutical composition is obviously better than pure Chinese medicine composition or alone chemical medicine fumaric acid tiamulin in treatment piglet mycoplasma pneumonia, effectively can cure mycoplasma pneumonia, and equal significant differences compared with blank group.
The observation of test example 5 pairs of atrophic rhinitis preventive effects
Once there is atrophic rhinitis in scale pig farm, Shandong Province, causes pig poor growth.Sick pig occurs that nose is askew, face distortion, and the symptoms such as canthus black tear speckle, have just started to belong to fragmentary appearance, after one by one case increase, be atrophic rhinitis through laboratory diagnosis.For control primary disease causes damage once again, then prevent.
1000 piglets are divided into 4 groups, are respectively A group, B group, C group and D group, often organize 250 piglets, A group, add the embodiment of the present invention 10 pharmaceutical composition 1 kilogram according to feedstuff per ton; B group, give the pure Chinese medicine composition of the embodiment of the present invention 10 of not buccal medicine tylosin phosphonate, feedstuff per ton adds 1 kilogram; C group, give 10% tylosin phosphonate pre-mixing agent, feedstuff per ton adds 2 kilograms; D group, does not add any medicine in feedstuff.Continuous use 14 days, after administration terminates, then continues observation 2 months, record affected animal number.Result of the test is in table 6.
Table 6 atrophic rhinitis prophylactic tria result
| Group | Test pig number (head) | Morbidity pig number (head) | Sickness rate (%) |
| A group | 250 | 0 | 0 |
| B group | 250 | 8 | 3.2 |
| C group | 250 | 7 | 2.8 |
| D group | 250 | 88 | 35.2 |
Result of the test shows, the embodiment of the present invention 10 pharmaceutical composition is obviously better than pure Chinese medicine composition or alone chemical medicine tylosin phosphonate in prevention atrophic rhinitis, effectively can prevent atrophic rhinitis, and equal significant differences compared with blank group.
The observation of test example 6 pairs of porcine respiratory disease preventive effects
Select have the pig farm of porcine respiratory disease morbidity history to carry out prophylactic tria observation.Scale pig farm, Baoding, Hebei province is invaded and harassed because of respiratory tract disease, and economic loss is serious, therefore selects this pig farm to carry out preventive effect evaluation.
The 28 days ablactational baby pig in 320, this pig farm are divided into 4 groups at random, often organize 80 piglets.1st group, add the embodiment of the present invention 11 pharmaceutical composition 250 grams according to feedstuff per ton; 2nd group, give the pure Chinese medicine composition of the embodiment of the present invention 11 of not buccal medicine kitasamycin, feedstuff per ton adds 1 kilogram; 3rd group, give 10% kitasamycin pre-mixing agent, feedstuff per ton adds 1 kilogram; 4th group, in feedstuff, do not add any medicine.Continuous use 14 days, after administration terminates, then continues observation 14 days, record affected animal number, dead animal number, and body weight during on-test and after off-test.Result of the test is in table 7.
Table 7 porcine respiratory disease prophylactic tria result
| Group | Test pig number (head) | Morbidity pig number (head) | Sickness rate (%) | Average initial weight (kg) | Average end heavy (kg) | Average weight gain (kg) | Body weight increase rate (%) |
| 1st group | 80 | 0 | 0 | 7.78±1.13 | 19.88 | 12.10 | 106.6 |
| 2nd group | 80 | 9 | 11.2 | 7.51±1.32 | 18.92 | 11.41 | 100.5 |
| 3rd group | 80 | 5 | 6.2 | 7.59±1.05 | 19.09 | 11.50 | 101.3 |
| 4th group | 80 | 31 | 38.8 | 7.80±1.15 | 19.15 | 11.35 | 100 |
Result of the test shows, the embodiment of the present invention 11 pharmaceutical composition is obviously better than pure Chinese medicinal preparation or alone chemical medicine kitasamycin in prevention porcine respiratory disease, effectively can prevent porcine respiratory disease, and equal significant differences compared with blank group; In growth promotion, the embodiment of the present invention 11 pharmaceutical composition is also significantly better than pure Chinese medicine composition or alone chemical medicine kitasamycin, and using dosage is low.Each group of duration of test is showed no pig death.
The observation of test example 7 pairs of swine flue preventive effects
Select have the pig farm, Fangshan, Beijing of swine flue medical history to carry out swine flue prophylactic tria, growing and fattening pigs 1600 are divided into 4 groups at random, often organize 400.1st group, add the embodiment of the present invention 12 pharmaceutical composition 1 kilogram according to feedstuff per ton; 2nd group, give the pure Chinese medicine composition of the embodiment of the present invention 12 of not buccal medicine tilmicosin phosphate, feedstuff per ton adds 1 kilogram; 3rd group, give 20% tilmicosin phosphate pre-mixing agent, feedstuff per ton adds 1 kilogram; 4th group, in feedstuff, do not add any medicine.Continuous use 14 days, after administration terminates, continues observation 14 days.Result of the test is in table 8.
Table 8 swine flue prophylactic tria result
| Group | Test pig number (head) | Morbidity pig number (head) | Sickness rate (%) | Dead pig number (head) | Mortality rate (%) |
| 1st group | 400 | 0 | 0 | 0 | 0 |
| 2nd group | 400 | 55 | 13.8 | 1 | 0.25 |
| 3rd group | 400 | 149 | 37.2 | 3 | 0.75 |
| 4th group | 400 | 189 | 47.2 | 15 | 3.75 |
Result of the test shows, the embodiment of the present invention 12 pharmaceutical composition is obviously better than pure Chinese medicine compositions or alone chemical medicine tilmicosin phosphate in preventing swine influenza, can effective preventing swine influenza, and equal significant differences compared with blank group.
The observation of test example 8 pairs of mycoplasmal pneumonia of swine preventive effects
Select pig farm, Hebei to carry out mycoplasmal pneumonia of swine prophylactic tria, ablactational baby pig 1800 is divided into 4 groups at random, often organize 450.1st group, add the embodiment of the present invention 13 pharmaceutical composition 300 grams according to feedstuff per ton; 2nd group, give the pure Chinese medicine composition of the embodiment of the present invention 13 of not buccal medicine valnemulin hydrochloride, feedstuff per ton adds 1 kilogram; 3rd group, give 10% valnemulin hydrochloride premix, feedstuff per ton adds 1 kilogram; 4th group, in feedstuff, do not add any medicine.Successive administration 14 days, after administration terminates, continues observation 14 days.Result of the test is in table 9.
Table 9 mycoplasmal pneumonia of swine prophylactic tria result
| Group | Test number (head) | Morbidity pig number (head) | Sickness rate (%) | Dead pig number (head) | Mortality rate (%) |
| 1st group | 450 | 0 | 0 | 0 | 0 |
| 2nd group | 450 | 32 | 7.1 | 2 | 0.4 |
| 3rd group | 450 | 9 | 2 | 1 | 0.2 |
| 4th group | 450 | 127 | 28.2 | 7 | 1.6 |
Result of the test shows, the embodiment of the present invention 13 pharmaceutical composition is obviously better than pure Chinese medicine composition or alone chemical medicine valnemulin hydrochloride in prevention piglet mycoplasma pneumonia, effectively can prevent mycoplasma pneumonia, and using dosage is low, all significant difference compared with blank group.
The observation of test example 9 pairs of porcine respiratory disease preventive effects
Select have the scale pig farm, Shunyi, Beijing of porcine respiratory disease medical history to carry out porcine respiratory disease prophylactic tria.Nursery pig 3200 is divided into 4 groups at random, often organizes 800.1st group, add the embodiment of the present invention 12 pharmaceutical composition 1 kilogram according to feedstuff per ton; 2nd group, give the pure Chinese medicine composition of the embodiment of the present invention 12 of not buccal medicine tilmicosin phosphate, feedstuff per ton adds 1 kilogram; 3rd group, give the pure Chinese medicine composition (CN201310200797.5) be made up of 7 grams, Herba Ephedrae, Semen Armeniacae Amarum 6 grams, Herba Artemisiae Scopariae 3 grams, Fructus Arctii 2 grams, Semen Lepidii (Semen Descurainiae) 2 grams, feedstuff per ton adds 1 kilogram; 4th group, in feedstuff, do not add any medicine.Continuous use 14 days, after administration terminates, continues observation 14 days.Result of the test is in table 10.
Table 10 porcine respiratory disease prophylactic tria result
| Group | Test pig number (head) | Morbidity pig number (head) | Sickness rate (%) | Dead pig number (head) | Mortality rate (%) |
| 1st group | 800 | 0 | 0 | 0 | 0 |
| 2nd group | 800 | 26 | 3.2 | 5 | 0.6 |
| 3rd group | 800 | 65 | 8.1 | 13 | 1.6 |
| 4th group | 800 | 82 | 10.2 | 35 | 4.3 |
Result of the test shows, the embodiment of the present invention 12 pharmaceutical composition prevention porcine respiratory disease in be obviously better than the present embodiment 12 not phosphoric acid tilmicosin pure Chinese medicine composition and by Herba Ephedrae, Semen Armeniacae Amarum, Herba Artemisiae Scopariae, Fructus Arctii, the molecular pure Chinese medicine composition of Semen Lepidii, efficiently can prevent porcine respiratory disease, and compared with blank group significant difference; The present embodiment 12 not phosphoric acid tilmicosin pure Chinese medicine composition prevention porcine respiratory disease in significantly better than by Herba Ephedrae, Semen Armeniacae Amarum, Herba Artemisiae Scopariae, Fructus Arctii, the molecular pure Chinese medicine composition of Semen Lepidii, significantly can reduce the M & M of porcine respiratory disease.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the prerequisite not departing from the technology of the present invention principle; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (7)
1. for preventing and treating a pharmaceutical composition for porcine respiratory disease, it is characterized in that, comprising following weight parts component: Chinese medicine ingredients 40-95 part, chemical medicine composition 1-60 part; Described Chinese medicine ingredients is made up of the component of following weight parts: Fructus Arctii 1-30 part, Semen Lepidii (Semen Descurainiae) 1-30 part, Rhizoma Dioscoreae 10-80 part; Described chemical medicine composition is selected from florfenicol, tilmicosin, taimulin, valnemulin, Aivlosin, tylosin, kitasamycin and salt thereof.
2. pharmaceutical composition according to claim 1, is characterized in that, comprises following weight parts component: Chinese medicine ingredients 50-90 part, chemical medicine composition 5-50 part; Described Chinese medicine ingredients is made up of the component of following weight parts: Fructus Arctii 3-20 part, Semen Lepidii (Semen Descurainiae) 3-20 part, Rhizoma Dioscoreae 30-70 part; Described chemical medicine composition is selected from florfenicol, tilmicosin, taimulin, valnemulin, Aivlosin, tylosin, kitasamycin and salt thereof.
3. pharmaceutical composition according to claim 2, is characterized in that, comprises following weight parts component: Chinese medicine ingredients 60-85 part, chemical medicine composition 10-40 part; Described Chinese medicine ingredients is made up of following ingredients weight parts: Fructus Arctii 6-15 part, Semen Lepidii (Semen Descurainiae) 6-15 part, Rhizoma Dioscoreae 40-60 part; Described chemical medicine composition is selected from florfenicol, tilmicosin, taimulin, valnemulin, Aivlosin, tylosin, kitasamycin and salt thereof.
4. pharmaceutical composition according to claim 3, is characterized in that, comprises following weight parts component: Chinese medicine ingredients 80 parts, chemical medicine composition 20 parts; Described Chinese medicine ingredients is made up of the component of following weight parts: Fructus Arctii 10 parts, Semen Lepidii (Semen Descurainiae) 10 parts, Rhizoma Dioscoreae 50 parts; Described chemical medicine composition is selected from florfenicol, tilmicosin, taimulin, valnemulin, Aivlosin, tylosin, kitasamycin and salt thereof.
5. a preparation method for the pharmaceutical composition described in any one of claim 1-4, comprises the steps:
(1) take each taste Chinese medicine by weight ratio respectively, Fructus Arctii, Semen Lepidii (Semen Descurainiae), Rhizoma Dioscoreae powder are broken into fine powder, obtain Chinese medicine ingredients;
(2) by weight taking Chinese medicine ingredients and chemical medicine composition respectively again, by the two mix homogeneously, to obtain final product.
6. the application of the pharmaceutical composition described in any one of claim 1-4 in preparation control porcine respiratory disease medicine.
7. comprise a premix material for the pharmaceutical composition described in any one of claim 1-4, batch or particulate material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410020332.6A CN104784411A (en) | 2014-01-17 | 2014-01-17 | Pig respiratory tract diseases prevention and treatment drug composition, premix and matching material thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410020332.6A CN104784411A (en) | 2014-01-17 | 2014-01-17 | Pig respiratory tract diseases prevention and treatment drug composition, premix and matching material thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104784411A true CN104784411A (en) | 2015-07-22 |
Family
ID=53549905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410020332.6A Pending CN104784411A (en) | 2014-01-17 | 2014-01-17 | Pig respiratory tract diseases prevention and treatment drug composition, premix and matching material thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104784411A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106366143A (en) * | 2016-08-30 | 2017-02-01 | 河北舒凯生物科技有限公司 | Tylosin lactate compounds, and composition and application thereof |
| CN107789322A (en) * | 2017-10-31 | 2018-03-13 | 成都乾坤动物药业股份有限公司 | A kind of new valnemulin pre-mixing agent and its preparation technology and application |
| CN108567979A (en) * | 2017-08-29 | 2018-09-25 | 江苏农牧科技职业学院 | One kind having treatment porcine respiratory disease eupatorium lindleynun var. trifoliolatum granule |
-
2014
- 2014-01-17 CN CN201410020332.6A patent/CN104784411A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 易本驰等: "《养猪科学用药指南》", 31 January 2009, 河南科学技术出版社 * |
| 王本祥: "《现代中药药理与临床》", 30 June 2004, 天津科技翻译出版公司 * |
| 郑继方等: "《中兽医诊疗手册》", 31 March 2006, 金盾出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106366143A (en) * | 2016-08-30 | 2017-02-01 | 河北舒凯生物科技有限公司 | Tylosin lactate compounds, and composition and application thereof |
| CN108567979A (en) * | 2017-08-29 | 2018-09-25 | 江苏农牧科技职业学院 | One kind having treatment porcine respiratory disease eupatorium lindleynun var. trifoliolatum granule |
| CN107789322A (en) * | 2017-10-31 | 2018-03-13 | 成都乾坤动物药业股份有限公司 | A kind of new valnemulin pre-mixing agent and its preparation technology and application |
| CN107789322B (en) * | 2017-10-31 | 2020-05-15 | 成都乾坤动物药业股份有限公司 | Valnemulin premix and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006892A (en) | Medicine composition for preventing and treating porcine viral diseases, and premix and batch with composition | |
| CN104543408A (en) | Chinese herbal medicine immunoregulator and application thereof in piglet breeding | |
| CN104258047A (en) | Traditional Chinese medicine composition for preventing and treating porcine reproductive and respiratory syndrome | |
| CN103006758A (en) | Chinese medicament composition for treating infectious bursal disease and preparation method thereof | |
| CN104784411A (en) | Pig respiratory tract diseases prevention and treatment drug composition, premix and matching material thereof | |
| CN107047469B (en) | A kind of cultural method for improving pig body immunity, preventing and treating swine disease | |
| CN103623121B (en) | A kind of for thousand order Chinese veterinary drug preparation of preventing and treating livestock and birds respiratory disease and preparation method thereof | |
| CN102133213B (en) | Veterinary compound florfenicol injection and preparation method thereof | |
| CN111603514A (en) | A traditional Chinese medicine compound preparation for veterinary anti-mycoplasma infection and its preparation method and use | |
| CN103141704A (en) | Traditional Chinese medicine feed for treating swine plague | |
| CN106214755A (en) | A kind of grippal Therapeutic Method of trimester of pregnancy sow | |
| CN102727693B (en) | Compound propolis composition used for treating swine toxoplasmosis, and preparation method thereof | |
| CN104367670A (en) | Traditional Chinese medicine granules for preventing and treating piglet bacterial enteritis and preparation method thereof | |
| CN103585407B (en) | Chinese medicine composition for the treatment of pig infectious atrophic rhinitis and preparation method thereof | |
| CN102247399B (en) | Medicament composite and injecta for treating swine streptococcosis | |
| CN105943931A (en) | Traditional Chinese medicine composition for treating swine plague and preparation method thereof | |
| CN105233063A (en) | Traditional Chinese medicine composition for preventing fowl cholera and preparation method thereof | |
| CN101953879B (en) | Microecological preparation for quickly and efficiently preventing and treating swine high fever | |
| CN105748873A (en) | Veterinary traditional Chinese medicine particle for treating livestock and poultry respiratory tract infection | |
| CN104887945B (en) | It is a kind of to be used to treat Chinese medicine composition of lamb pneumonia and its preparation method and application | |
| CN101279029B (en) | Liquid oral vaccine for curing blue-ear pig disease and method of preparing the same | |
| CN108042690B (en) | Traditional Chinese medicine composition for treating swine mycoplasma pneumonia and application thereof | |
| CN103263483B (en) | Medicament used for treating livestock virus and bacteria infections and prepared from traditional Chinese medicines and preparation method of medicament | |
| CN107233418A (en) | A kind of composition, preparation method and its application method for being used to prevent and treat porcine hyperthermia | |
| CN107281368A (en) | A kind of feed addictive for preventing and treating swine plague |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150722 |